Transferases

Glycogen phosphorylase-IN-1 is a potent inhibitor of human liver glycogen phosphorylase (hlGPa), demonstrating IC50 values of 53 nM for the enzyme and 380 nM for glucose production from hepatocyte glycogen. This compound is particularly relevant for research applications targeting type 2 diabetes, as it effectively reduces glycogen-derived glucose production in hepatocytes, thereby influencing glucose homeostasis.

BAY R3401 is an orally active inhibitor of glycogen phosphorylase, demonstrating irreversible and non-selective inhibition of hepatic glycogenolysis. This compound effectively inhibits glycogenolysis in liver cells, exhibiting IC50 values of 27.06 μM in HL-7702 cells and 52.83 μM in HepG2 cells. BAY R3401 serves as a valuable tool for research focused on type 2 diabetes and its associated metabolic pathways.

GPi688 is a potent and orally active inhibitor of glycogen phosphorylase (GPa), demonstrating IC50 values of 19 nM, 61 nM, and 12 nM for human liver GPa, rat liver GPa, and human skeletal muscle GPa, respectively. This compound effectively inhibits glucagon-mediated glucose output in rat primary hepatocytes. GPi688 is a valuable tool for investigating glucagon-mediated hyperglycemia and related metabolic disorders in research applications.

Deoxyadenosine diphosphate sodium is a nucleoside diphosphate that functions as a phosphorylase inhibitor. It plays a crucial role in DNA synthesis and repair processes by inhibiting polynucleotide phosphorylase, thereby interfering with the polymerization of ADP and CDP. This compound is valuable for research applications focused on understanding DNA metabolism and enzymatic regulation in cellular systems.

TK-112690 is a selective inhibitor of uridine phosphorylase 1 (UPP1). It demonstrates inhibitory effects on murine small intestinal uridine phosphorylase with an IC50 of 12.5 μM and on human small intestinal UPP1 with an IC50 of 20.0 μM in vitro. By increasing plasma uridine concentration in mice, TK-112690 can be utilized to explore therapeutic avenues in cancer research and pulmonary fibrosis studies.